☰

Meagan E. Anderson, Ph.D.

Affiliations: 
2003 University of Kansas, Lawrence, KS, United States 
Area:
Pharmaceutical Chemistry, Pharmacology
Google:
"Meagan Anderson"
Mean distance: (not calculated yet)
 
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Teruna J. Siahaan grad student 2003 University of Kansas
 (Utilization of ICAM-1 derived peptides for targeted drug delivery to T-cells.)

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Majumdar S, Anderson ME, Xu CR, et al. (2012) Methotrexate (MTX)-cIBR conjugate for targeting MTX to leukocytes: conjugate stability and in vivo efficacy in suppressing rheumatoid arthritis. Journal of Pharmaceutical Sciences. 101: 3275-91
Anderson ME, Tejo BA, Yakovleva T, et al. (2006) Characterization of binding properties of ICAM-1 peptides to LFA-1: inhibitors of T-cell adhesion. Chemical Biology & Drug Design. 68: 20-8
Dunehoo AL, Anderson M, Majumdar S, et al. (2006) Cell adhesion molecules for targeted drug delivery. Journal of Pharmaceutical Sciences. 95: 1856-72
Anderson ME, Yakovleva T, Hu Y, et al. (2004) Inhibition of ICAM-1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides. Bioorganic & Medicinal Chemistry Letters. 14: 1399-402
Anderson ME, Siahaan TJ. (2003) Mechanism of binding and internalization of ICAM-1-derived cyclic peptides by LFA-1 on the surface of T cells: a potential method for targeted drug delivery. Pharmaceutical Research. 20: 1523-32
Anderson ME, Siahaan TJ. (2003) Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides. 24: 487-501
Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, et al. (2002) Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Medicinal Research Reviews. 22: 146-67
See more...